CRISPR Targets Gene Fusions Behind One in Five Cancers

CRISPR Targets Gene Fusions in a breakthrough that could change how doctors treat one of cancer's most common triggers. Scientists in Australia have reprogrammed the gene-editing system to hunt down the exact point where two genes fused together wrongly and silence the message that drives tumors. According to a study published in Science Advances, the technique worked on nine different gene fusions in laboratory tests, a result the researchers call a step toward medicines built around each patient's own tumor.

Gene fusions happen when DNA breaks inside a cell and gets stitched back together incorrectly, joining pieces of two separate genes into one hybrid. These hybrids show up in roughly one in five of all cancers, and the paper describes them as genuine cancer drivers in about a sixth of cases. To put that in familiar terms, the fusion called BCR-ABL1 appears in nearly every case of chronic myeloid leukemia, a blood cancer, while EWSR1-FLI1 turns up in the vast majority of cases of Ewing sarcoma, a rare cancer of bone and surrounding soft tissue.

The new method works differently from the CRISPR most people have heard about. Instead of cutting DNA, the team used molecular scissors called Cas13 that chew up RNA, the working instructions a gene sends out. Programmed to recognize the junction where the two fused genes meet, the scissors ignore the normal copies of each gene and destroy only the hybrid message. That junction is a fingerprint that exists only in cancer cells, which is why the approach can be so precise.

How the reprogrammed scissors work

"Gene fusions create a unique molecular fingerprint that we can use for highly precise targeting," said Wenxin Hu, one of the study's authors, in a statement. "Instead of developing a completely different technology for every cancer, we can reprogram the CRISPR system to recognize different genetic drivers in individual tumors, bringing us one step closer to personalized cancer treatment."

Because each patient's fusion pattern can differ slightly, the therapy could be tailored to match the specific tumor, rather than forcing patients onto one-size-fits-all drugs. Dr. Mohamad Fareh, who led the work at the Melbourne-based Peter Mac research institute, said the strategy focuses on "a unique fingerprint found only in cancer cells," adding that it could apply across many blood and solid tumors.

The comparison with existing targeted drugs is instructive. Medicines that block the activity of the fused protein have transformed outcomes for some patients with leukemia. But fusions vary wildly between cancers, and designing a new blocker for each one takes years. A programmable system that can be redirected by swapping the recognition sequence would, in theory, shrink that timeline dramatically.

What comes next

There is a large caveat, and the researchers state it plainly. The method has only been demonstrated in laboratory cell models so far, according to the study. It has not been tested in animals or in people. The next hurdle is delivery: getting the CRISPR machinery into tumors inside the body and proving it hits cancer cells selectively in a far more complex environment.

"Our long-term vision is to develop programmable cancer medicines that can be tailored to the genetic abnormalities driving an individual tumor," said Fareh. "This study provides an important step toward turning the genetic information we can now identify in cancers into new ways of treating them."

That caution matters for anyone tempted to read a lab result as a coming cure. The history of gene therapy is full of elegant ideas that stumbled on delivery. Still, the team notes that the pace of CRISPR delivery research, from lipid carriers to targeted nanoparticles, has accelerated in recent years, which gives the approach a clearer runway than similar ideas had a decade ago.

Why it matters for you

Most of us will never have a gene fusion show up on a pathology report, but cancer touches nearly every family, and the economic burden of one-size-fits-all treatments is enormous. If a single programmable platform could be tuned to many fusions instead of requiring a bespoke drug per target, the cost and speed of bringing new cancer therapies to patients could shift meaningfully. For now, the takeaway is to watch the delivery trials: that is where this idea will either become medicine or stay a laboratory proof of concept.

Cancer research has been stacking wins this month. GenZ NewZ covered a five-year teen brain study finding that social connection and mindfulness predicted wellbeing more strongly than sleep advice, and new research on campus resilience showing everyday habits track with how students recover from stress.

The paper, by Wenxin Hu and colleagues, appeared in the journal on October 19, 2026. Source material for this article was reported by Medical Xpress.